Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants

This article has been Reviewed by the following groups

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants of concern (VOC), such as Delta (B.1.617.2) and Omicron (B.1.1.529), has continued to drive the worldwide pandemic. Therefore, there is a high demand for vaccines with enhanced efficacy, high thermostability, superior design flexibility, and fast manufacturing speed. Here, we report a circular RNA (circRNA) vaccine that encodes the trimeric RBD of SARS-CoV-2 Spike protein. Without the need of nucleotide modification, 5’-capping or 3’-polyadenylation, circRNA could be rapidly produced via in vitro transcription and is highly thermostable whether stored in naked or lipid-nanoparticle (LNP)-encapsulated format. LNP-encapsulated circRNA RBD elicited potent neutralizing antibodies and T cell responses, providing robust protection against Beta (B.1.351) and native viruses in mice and rhesus macaques, respectively. Notably, circRNA vaccine enabled higher and more durable antigen production than 1mΨ-modified mRNA vaccine, eliciting a higher proportion of neutralizing antibodies and stronger Th1-biased immune responses. Importantly, we found that circRNA RBD-Omicron vaccine induced effective neutralizing antibodies against only Omicron but not Delta variant. By contrast, circRNA RBD-Delta could elicit high level of neutralizing antibodies against both Delta and Omicron. Following two doses of either native- or Delta-specific vaccination, circRNA RBD-Delta , but not Omicron or Beta vaccines, could effectively boost the neutralizing antibodies against both Delta and Omicron variants. These results suggest that circRNA RBD-Delta is a favorable choice for vaccination to provide a broad-spectrum protection against the current variants of concern of SARS-CoV-2.

Article activity feed

  1. SciScore for 10.1101/2021.03.16.435594: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIACUC: The animal experiments were approved by Peking University Laboratory Animal Center (Beijing), and undertaken in accordance with the National Institute of Health Guide for Care and Use of Laboratory Animals.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variableFor mouse vaccination, groups of 6-8 week-old female BLAB/c mice were intramuscularly immunized with LNP-circRNARBD (10 μg, N = 5; 50 μg, N = 5), or Placebo (empty LNP, N = 5) in 150 μL using a 1 mL sterile syringe, and 2 weeks later a second dose was immunized to boost the immune responses.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    The SARS-CoV-2-specific IgG antibody titer was measured by ELISA.
    SARS-CoV-2-specific IgG
    suggested: None
    Cells were then washed in stain buffer (PBS supplemented with 2.5% FBS) and suspended in Fc Block for 5 min at RT prior to staining with a surface stain of following antibodies: CD3 (Invitrogen, 45-0031-82)/CD4 (BD, 562285)/CD8 (BD, 553035)/CD69 (BD, 557392)/CD44 (BD, 563058)/CD62L (BD, 560507).
    CD3
    suggested: (Abcam Cat# ab52305, RRID:AB_955118)
    Experimental Models: Cell Lines
    SentencesResources
    circRNA transfection in vitro: For the circRNA transfection in HEK293T or NIH3T3 cells, 3×105 cells per well were seeded in 12-well plates.
    NIH3T3
    suggested: None
    Then the supernatant of HEK293T-hACE2 cells were removed and the mixer of serum and pseudovirus were added to each well. 36-48 hr later, the luciferase activity, which reflecting the degree of SARS-CoV-2 pseudovirus transfection, was measured using the Nano-Glo Luciferase Assay System (Promega).
    HEK293T-hACE2
    suggested: None
    Briefly, serum was diluted at 1:100 with 5 additional serial 5-fold dilution, and incubated with the same volume of pseudovirus with a TCID50 of 1.3×104 for 60 min at 37°C. 20,000 Huh-7 cells/well were cultured with mixture at 37°C for 24 h.
    Huh-7
    suggested: None
    Expression of neutralizing nanobodies or ACE2 decoys by circular RNAs: HEK293T cells were transfected with circular RNA in transfection reagent.
    HEK293T
    suggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)
    Experimental Models: Organisms/Strains
    SentencesResources
    Mouse vaccination and serum collection: The BALB/c mice were ordered from Beijing Vital River Laboratory Animal Technology Co., Ltd.
    BALB/c
    suggested: RRID:IMSR_ORNL:BALB/cRl)
    For mouse vaccination, groups of 6-8 week-old female BLAB/c mice were intramuscularly immunized with LNP-circRNARBD (10 μg, N = 5; 50 μg, N = 5), or Placebo (empty LNP, N = 5) in 150 μL using a 1 mL sterile syringe, and 2 weeks later a second dose was immunized to boost the immune responses.
    BLAB/c
    suggested: None
    Software and Algorithms
    SentencesResources
    The half-neutralization titer of serum (NT50) was determined using four-parameter nonlinear regression in Prism 8 (GraphPad).
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)
    Relative luciferase units (RLU) were normalized to untreated groups, and analyzed by four-parameter nonlinear regression in Prism (GraphPad).
    Prism
    suggested: (PRISM, RRID:SCR_005375)
    For the neutralization assay of circRNAnAB or circRNAACE2 decoys, the HEK293T-hACE2 cells were seeded in 96-well plates (50,000 cells/well) and incubated for approximate 24 hr until reaching over 90% confluent.
    circRNAnAB
    suggested: None
    Analysis was performed using FlowJo software.
    FlowJo
    suggested: (FlowJo, RRID:SCR_008520)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


    Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 19. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.